Key result
In silico analysis identified conserved 23-nucleotide target sequences across SARS-CoV-2, SARS-CoV, MERS-CoV, and other human coronaviruses for potential CRISPR-Cas13d antiviral strategies.
Why the study?
The SARS-CoV-2 pandemic prompted the search for antiviral drugs, and tools like the CRISPR-Cas13d system could potentially be adapted as sequence-specific anti-coronavirus strategies.
In silico analysis identified conserved target sequences across human coronaviruses for potential CRISPR-Cas13d-based antiviral therapies.
CRISPR-Cas13d antiviral design for SARS-CoV-2 remains preclinical; leaves open therapeutic translation pending in vivo efficacy data.
The SARS-CoV-2 pandemic has urged the development of protective vaccines and the search for specific antiviral drugs. The modern molecular biology tools provides alternative methods, such as CRISPR-Cas and RNA interference, that can be adapted as antiviral approaches, and contribute to this search. The unique CRISPR-Cas13d system, with the small crRNA guide molecule, mediates a sequence-specific attack on RNA, and can be developed as an anti-coronavirus strategy. We analyzed the SARS-CoV-2 genome to localize the hypothetically best crRNA-annealing sites of 23 nucleotides based on our extensive expertise with sequence-specific antiviral strategies. We considered target sites of which the sequence is well-conserved among SARS-CoV-2 isolates. As we should prepare for a potential future outbreak of related viruses, we screened for targets that are conserved between SARS-CoV-2 and SARS-CoV. To further broaden the search, we screened for targets that are conserved between SARS-CoV-2 and the more distantly related MERS-CoV, as well as the four other human coronaviruses (OC43, 229E, NL63, HKU1). Finally, we performed a search for pan-corona target sequences that are conserved among all these coronaviruses, including the new Omicron variant, that are able to replicate in humans. This survey may contribute to the design of effective, safe, and escape-proof antiviral strategies to prepare for future pandemics.
No takes yet. Share an insight, caveat, or question.
Hussein et al. (2022) studied SARS-CoV-2 and other human coronaviruses. In silico prediction of CRISPR-Cas13d target sequences was evaluated on Identification of conserved crRNA-annealing sites. In silico analysis identified conserved 23-nucleotide target sequences across SARS-CoV-2, SARS-CoV, MERS-CoV, and other human coronaviruses for potential CRISPR-Cas13d antiviral strategies.
Synapse has enriched 5 closely related papers on similar clinical questions. Consider them for comparative context: